Jan 19 | News
NEW YORK (AP) — Celebrity chef Paula Deen on Wednesday pledged a portion of her earnings from a lucrative endorsement deal with a diabetes drugmaker to the nonprofit American Diabetes Association.
|
Jan 18 | News
NEW YORK (AP) — Paula Deen, the Southern belle of butter and heavy cream, makes no apologies for waiting three years to disclose she has diabetes while continuing to dish up deep-fried cheesecake and other high-calorie, high-fat recipes on TV.
|
Dec 15 2011 | News
Enlight Biosciences LLC announced today that it has formed new partnerships with AstraZeneca and Novo Nordisk. As partners in Enlight, AstraZeneca and Novo Nordisk will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs.
|
Nov 4 2011 | News
Novo Nordisk said it would not pursue mergers and acquisitions in China and would instead expand by strengthening its R&D activity, building manufacturing facilities and enhancing education, China Daily reported Thursday.
|
Aug 2 2011 | News
Novo Nordisk has announced a $215M redevelopment project that will serve as the company's new U.S.
headquarters.
|
Feb 16 2011 | News
Novo Nordisk A/S says it has been
subpoenaed by the U.S. Attorney for the District of Massachusetts in an
investigation of how the Danish pharmaceutical company markets three diabetes
drugs.
|
Jan 24 2011 | News
Specialty drugmaker Pacira Pharmaceuticals Inc. has licensed its
DepoFoam drug delivery technology to Novo Nordisk AS in a deal that could be
worth more than $45.5 million.
|
Jan 20 2011 | News
Novo Nordisk announced that Judge Avern Cohn of the US
District Court for the Eastern District of Michigan issued an adverse ruling in
a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The
district court ruled that the patent, which covers the combination use of
repaglinide and metformin for the treatment of type 2 diabetes, is invalid and
unenforceable.
|
Dec 22 2010 | News
Merrion Pharmaceuticals Plc, has announced the signing of a
Collaboration and Option agreement with Novo Nordisk. The agreement will
evaluate the ability of Merrion's patented GIPET(R) technology to boost the
oral bioavailability of an undisclosed proprietary compound.
|
Oct 5 2010 | News
RALEIGH, N.C. (AP) — Two companies plan to create 241 jobs over the next four
years in North Carolina as they expand production of a new insulin device for
people with diabetes.
|